Esophageal cancer is one of the most common and deadliest cancers worldwide. Rates of esophageal cancer worldwide have been steadily rising over the past decade due to higher incidence of gastroesophageal reflux disease (GERD). Current therapies include surgical resection, chemotherapy, and limited targeted therapies. One obstacle to care is tumor cells’ ability to evade immune surveillance, which can render certain therapeutics ineffective. Immunotherapy provides a new paradigm to cancer treatment, which has proven to be effective in evasive tumors. In recent years, PD-1/PD-L1 and CLTA-4 inhibitors have been used as frontline treatment and have shown to be extremely effective in the treatment of hard-to-treat tumors. Here, we aim to analyze the current literature regarding current therapeutics along with emerging techniques and future receptor targets for immunotherapy.
食管癌是全球范围内最常见且致死率最高的恶性肿瘤之一。过去十年间，由于胃食管反流病发病率持续上升，全球食管癌发生率呈稳步增长态势。当前治疗手段主要包括手术切除、化疗及有限的靶向治疗。临床治疗面临的主要障碍在于肿瘤细胞能够逃避免疫监视，导致部分治疗方案失效。免疫疗法为癌症治疗提供了全新范式，已被证实对具有免疫逃逸特性的肿瘤具有显著疗效。近年来，PD-1/PD-L1抑制剂及CLTA-4抑制剂已作为一线治疗方案应用于临床，在难治性肿瘤治疗中展现出卓越疗效。本文旨在系统评述现有治疗方案的文献依据，并探讨免疫治疗领域新兴技术及未来受体靶点的研究进展。
Current Advances in Immunotherapy Management of Esophageal Cancer
肿瘤(癌症)患者之家